<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991923</url>
  </required_header>
  <id_info>
    <org_study_id>NIHP2019</org_study_id>
    <nct_id>NCT03991923</nct_id>
  </id_info>
  <brief_title>Non-ischemic Preservation of the Donor Heart in Heart Transplantation</brief_title>
  <official_title>Non-ischemic Preservation of the Donor Heart in Heart Transplantation - a Randomized, Controlled, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XVIVO Perfusion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XVIVO Perfusion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study intends to compare standard ischemic cold static storage (ICSS) of retrieved hearts
      intended to be transplanted, to non-ischemic heart preservation (NIHP) in a randomized
      clinical multicentre trial. The primary hypothesis is that the non-ischemic hypothermic
      cardioplegic preservation (NIHP) is safe and superior to ischemic cold static storage (ICSS)
      of donor hearts. The study will investigate the safety and superiority of the new methodology
      in terms of improved immediate and prolonged organ function in adult heart transplanted
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate if non-ischemic heart preservation (NIHP) with the XVIVO heart
      preservation devices could improve clinical outcome of patients receiving hearts after use of
      the technology compared to after use of standard cold ischemic preservation. This will be
      investigated in a European multicentre randomized controlled clinical trial. For technical
      reasons, blinding to the involved clinical personnel is not possible, however, biopsies will
      be blinded to study pathologists. The trial will include 202 recipients that have been
      randomized through their heart donor. The primary outcome of the study is a clinically
      relevant composite including graft survival, primary graft dysfunction, rejection and use of
      circulatory mechanical support, within 30 days and also including Cardiac Allograft
      Vasculopathy within 12 months. As secondary outcomes, molecular markers related to cardiac
      injury CKMB, ProBNP and TNI will be investigated as well as markers of the inflammatory
      response. Safety aspects such as effect on other organs and machine defects will also be
      monitored. The study population is adults, listed for heart transplantation and donors
      accepted as heart donors according to standard hospital procedures. Specific recipient
      exclusion criteria related to pre-transplant ECMO support, patients undergoing pre-transplant
      desensitization protocol, patients with Grown-Up Congenital Heart Disease, patients with
      severe kidney or liver dysfunction, patients with septicaemia, and patients diagnosed with
      Systemic Lupus Erythematous, sarcoidosis or amyloidosis are excluded. Cardiac death donors
      and donors with previous sternotomy are excluded. The study hypothesis is that NIHP better
      preserves the endothelium and myocyte function of the heart resulting in improved short- and
      medium-term recipient outcome, without inducing any new significant risks to the retrieved
      heart or the recipient. This is believed to be accomplished through continuous oxygenation of
      the heart via perfusion of the coronary arteries using an optimized preservation solution,
      mimicking the normal environment for the endothelium.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30 days mortality and 30 days graft dysfunction</measure>
    <time_frame>30 days</time_frame>
    <description>The Primary End-Point is defined as time-to-first-event of cardiac related death, moderate or severe primary graft dysfunction of the left ventricle or primary graft dysfunction of the right ventricle (according to Kobashigawa et al., 2014), acute cellular rejection ≥2R (according to Stewart et al., 2005) or graft failure (use of mechanical circulatory support or retransplantation) within 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 year mortality and 1 year graft dysfunction</measure>
    <time_frame>1 year</time_frame>
    <description>The key secondary endpoint is defined as time-to-first-event of either any cause of death, moderate or severe PGD-LV or PGD-RV (according to Kobashigawa et al., 2014), acute cellular rejection ≥2R (according to Stewart et al., 2005) or graft failure (use of mechanical circulatory support or retransplantation) or CAV ≥ 1 (according to Mehra, 2010) within 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 days and 1 year mortality and graft dysfunction</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>The individual variables included in the composite primary endpoint at 30 days and 1 year analyzed as time-to-first-event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CKMB</measure>
    <time_frame>3 days</time_frame>
    <description>Creatine kinase MB (CKMB) at 6 ±2 h, 24 ±6 h, 48±6 h and 72±6 h after cross clamp removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TnI</measure>
    <time_frame>3 days</time_frame>
    <description>Tropinin I (TnI) at 6 ±2 h, 24 ±6 h, 48±6 h and 72±6 h after cross clamp removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ProBNP</measure>
    <time_frame>3 days</time_frame>
    <description>Pro Brain Natriuretic Protein (ProBNP) at 6 ±2 h, 24 ±6 h, 48±6 h and 72±6 h after cross clamp removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stay in ICU</measure>
    <time_frame>1 year</time_frame>
    <description>Length of Stay at Intensive Care Unit, reported as number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Transplant Events</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of Major Adverse Cardiac Transplant Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative use of mechanical circulatory support</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of use of postoperative mechanical circulatory support, reported as number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative duration of mechanical circulatory support</measure>
    <time_frame>1 year</time_frame>
    <description>Duration of use of postoperative mechanical circulatory support, reported as number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall success/failure 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Success is defined as a recipient that are transplanted and alive at 30 days without any of the complication in the primary endpoint before 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall success/failure 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>Success is defined as a recipient that are transplanted and alive at 1 year without any of the complication given in key secondary endpoint before 1 year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO data (Left ventricular ejection fraction)</measure>
    <time_frame>24 hours</time_frame>
    <description>ECHO data with Left ventricular ejection fraction in percentage within 24 hours after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO data (Left ventricular ejection fraction)</measure>
    <time_frame>1 week</time_frame>
    <description>ECHO data with Left ventricular ejection fraction in percentage 1 week after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO data (Left ventricular ejection fraction)</measure>
    <time_frame>6 months</time_frame>
    <description>ECHO data with Left ventricular ejection fraction in percentage 6 months after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO data (Left ventricular ejection fraction)</measure>
    <time_frame>1 year</time_frame>
    <description>ECHO data with Left ventricular ejection fraction in percentage 1 year after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO data (Right ventricular ejection fraction)</measure>
    <time_frame>24 hours</time_frame>
    <description>ECHO data with Right ventricular ejection fraction in percentage within 24 hours after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO data (Right ventricular ejection fraction)</measure>
    <time_frame>1 week</time_frame>
    <description>ECHO data with Right ventricular ejection fraction in percentage 1 week after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO data (Right ventricular ejection fraction)</measure>
    <time_frame>6 months</time_frame>
    <description>ECHO data with Right ventricular ejection fraction in percentage 6 months after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO data (Right ventricular ejection fraction)</measure>
    <time_frame>1 year</time_frame>
    <description>ECHO data with Right ventricular ejection fraction in percentage 1 year after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO data (Tricuspid annular plane systolic excursion)</measure>
    <time_frame>24 hours</time_frame>
    <description>ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm within 24 hours after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO data (Tricuspid annular plane systolic excursion)</measure>
    <time_frame>1 week</time_frame>
    <description>ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm 1 week after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO data (Tricuspid annular plane systolic excursion)</measure>
    <time_frame>6 months</time_frame>
    <description>ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm 6 months after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECHO data (Tricuspid annular plane systolic excursion)</measure>
    <time_frame>1 year</time_frame>
    <description>ECHO data with Tricuspid annular plane systolic excursion (TAPSE) in mm 1 year after transplantation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serious adverse device effects</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of any serious adverse device effects.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse device effects</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of any adverse device effects</description>
  </other_outcome>
  <other_outcome>
    <measure>Device dysfunction resulting in loss of transplantable heart</measure>
    <time_frame>12 hours</time_frame>
    <description>Number of transplantable hearts lost due to device dysfunction</description>
  </other_outcome>
  <other_outcome>
    <measure>Intra operative details; duration of ECC</measure>
    <time_frame>12 hours</time_frame>
    <description>Duration of ECC in minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Intra operative details; duration of cross clamp</measure>
    <time_frame>12 hours</time_frame>
    <description>Duration of cross clamp in minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Intra operative details; duration of surgery</measure>
    <time_frame>12 hours</time_frame>
    <description>Duration of surgery in minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Intra operative details; attempts to wean off ECC</measure>
    <time_frame>12 hours</time_frame>
    <description>Number of attempts to wean off ECC</description>
  </other_outcome>
  <other_outcome>
    <measure>Intra operative details; need for inotropic support</measure>
    <time_frame>12 hours</time_frame>
    <description>Need for inotropic support (inotropic score)</description>
  </other_outcome>
  <other_outcome>
    <measure>Intra operative details; need for pulmonary vasodilator</measure>
    <time_frame>12 hours</time_frame>
    <description>Need for pulmonary vasodilator</description>
  </other_outcome>
  <other_outcome>
    <measure>Intra operative details; defibrillations</measure>
    <time_frame>12 hours</time_frame>
    <description>Number of defibrillations</description>
  </other_outcome>
  <other_outcome>
    <measure>Intra operative details; arryhythmias</measure>
    <time_frame>12 hours</time_frame>
    <description>Occurence of arryhythmias</description>
  </other_outcome>
  <other_outcome>
    <measure>Intra operative details; conduction abnormalities</measure>
    <time_frame>12 hours</time_frame>
    <description>Number of conduction abnormalities</description>
  </other_outcome>
  <other_outcome>
    <measure>Intra operative details; Left ventricular ejection fraction (LVEF)</measure>
    <time_frame>12 hours</time_frame>
    <description>LVEF in percentage</description>
  </other_outcome>
  <other_outcome>
    <measure>Intra operative details; Right ventricular ejection fraction (RVEF)</measure>
    <time_frame>12 hours</time_frame>
    <description>RVEF in percentage</description>
  </other_outcome>
  <other_outcome>
    <measure>Intra operative details; Mitral valve regurgitations</measure>
    <time_frame>12 hours</time_frame>
    <description>Grade of mitral valve regurgitations</description>
  </other_outcome>
  <other_outcome>
    <measure>Intra operative details; Tricuspid valve regurgitations</measure>
    <time_frame>12 hours</time_frame>
    <description>Occurence of tricuspid vavle regurgitations</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial blood gas lactate</measure>
    <time_frame>6 hours</time_frame>
    <description>Arterial blood gas lactate at 6 hours</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial blood gas lactate</measure>
    <time_frame>24 hours</time_frame>
    <description>Arterial blood gas lactate at 24 hours</description>
  </other_outcome>
  <other_outcome>
    <measure>Pro-BNP during follow up</measure>
    <time_frame>1 year</time_frame>
    <description>Pro-BNP at predefined time points during follow-up.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Heart Transplantation</condition>
  <arm_group>
    <arm_group_label>Non-ischemic heart preservation (NIHP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continous cold cardioplegic perfusion of hearts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ischemic cold static storage (ICSS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard preservation technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XVIVO heart preservation devices</intervention_name>
    <description>The intervention is to preserve hearts during transportation cold, cardioplegic and non-ischemic, with a high oncotic and hormone supplemented perfusate.</description>
    <arm_group_label>Non-ischemic heart preservation (NIHP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard ICSS</intervention_name>
    <description>Cold static preservation using standard preservation solution</description>
    <arm_group_label>Ischemic cold static storage (ICSS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria recipient:

          -  Age ≥18 years

          -  Signed informed consent form

          -  Listed for heart transplantation

        Inclusion criteria donor:

          -  Age ≥18 and ≤70 years

          -  Accepted as heart donor by the transplant team

          -  (research consent from the donor if required in country)

        Exclusion Criteria recipient:

          -  Previous solid organ transplantation

          -  Grown-up congenital heart disease (GUCH)

          -  Kidney failure eGFR&lt;40 at listing, calculated by CDK-EPI Creatinine, or
             ultrafiltration or dialysis or rapidly deteriorating kidney function due to a
             diagnosed renal disease

          -  Coagulopathy due to known hepatic disease or heparin induced thrombocytopenia

          -  Patient diagnosed with Systemic Lupus Erythematous, sarcoidosis or amyloidosis

          -  Ongoing septicemia defined as positive blood culture (including with a durable VAD)

          -  Incompatible blood group

          -  Not able to understand the information provided during the informed consent procedure

          -  Combined organ transplantation candidates

          -  Patient already consented for another transplant related intervention study

          -  Patients under pre-transplant desensitization protocol

          -  Short term mechanical circulatory support pre-transplantation (Except for Intra-Aortic
             Balloon Pump)

        Exclusion criteria donor:

          -  Previous sternotomy

          -  DCD hearts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip Rega, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uz Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klara Thorsson</last_name>
    <phone>+46 (0)735192144</phone>
    <email>klara.thorsson@xvivoperfusion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Wallinder, MD, PhD</last_name>
    <phone>+46 (0)73-5192142</phone>
    <email>andreas.wallinder@xvivoperfusion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filip Rega</last_name>
      <phone>+3216344260</phone>
      <email>filip.rega@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de cardiologie, Chirurgie thoracique et cardiovasculaire La Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <state>Paris Cedex</state>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume Lebreton</last_name>
      <phone>+33672320194</phone>
      <email>guillaume.lebreton@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastian Michel</last_name>
      <phone>+49 89 44 00 73 468</phone>
      <email>Sebastian.michel@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda osedalaria di Padova</name>
      <address>
        <city>Padova</city>
        <state>Padova PD</state>
        <zip>35121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gino Gerosa</last_name>
      <phone>+39 32 99 07 48 53</phone>
      <email>Gino.gerosa@unipd.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Puerto de Hierro</name>
      <address>
        <city>Madrid</city>
        <state>Majadahonda Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Forteza</last_name>
      <phone>+34 63 62 75 497</phone>
      <email>apforteza@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <state>Västra Götalands Regionen</state>
        <zip>412 34</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Göran Dellgren</last_name>
      <phone>+46 (0) 31-342 88 63</phone>
      <email>goran.dellgren@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>Newcastle Upon Tyne</state>
        <zip>NE77DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Clark</last_name>
      <phone>+44 (0) 77 79 27 33 88</phone>
      <email>Stephen.clark@newcastle.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elisabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B152TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aaron Ranasinghe</last_name>
      <phone>+44 (0) 75 00 78 24 11</phone>
      <email>Aaron.ranasinghe@uhb.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Ischemic Heart Preservation (NIHP)</keyword>
  <keyword>Ischemic cold static storage of donor hearts (ICSS)</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

